Endogenous nitric oxide in cardiovascular disease and transplantation.
Nitric oxide (NO), derived from the vascular endothelium and other cells of the cardiovascular system, has important roles in physiological regulation of blood flow and may have pathophysiological functions in cardiovascular disease. The mechanisms involved in NO-induced vasodilatation and cytotoxicity are briefly reviewed in the context of inflammatory reactions and cardiovascular function. Although NO can hyperpolarize vascular smooth muscle, activation of the endothelium can induce hyperpolarization and vasodilatation by other means. Endogenous inhibitors of NO generated by leucocytes may compromise blood flow distribution after ischaemia and reperfusion injury. Chronic heart failure is associated simultaneously with impairment of endothelium-dependent vasodilatation and with excess production of NO via the inducible NO synthase (iNOS), although it is unclear whether the latter ameliorates or exacerbates ventricular dysfunction. Excess NO production is also one of the earliest signs of transplant rejection, and suppression of iNOS expression by immunosuppressant drugs such as cyclosporin A might be one means by which these drugs protect allografts. Disturbances in the activity of NOS isoforms in the artery wall also accompany the development of atherosclerosis, providing conditions propitious for vasospasm and thrombosis. Reversing the NO defects with therapeutic agents, including angiotensin converting enzyme (ACE) inhibitors, offers promise in protecting against some manifestations of vascular disease.
Dusting
G J
GJ
Department of Physiology, University of Melbourne, Victoria, Australia.
Macdonald
P S
PS
D017130:Angioplasty; D000818:Animals; D001161:Arteriosclerosis / Q000503:physiopathology; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology*; D004730:Endothelium, Vascular / Q000503:physiopathology; D006084:Graft Rejection / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology*; D006333:Heart Failure / Q000209:etiology; D016027:Heart Transplantation / Q000502:physiology*; D006801:Humans; D006937:Hypercholesterolemia / Q000503:physiopathology; D007166:Immunosuppressive Agents / Q000494:pharmacology; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D012008:Recurrence; D014664:Vasodilation / Q000502:physiology
D007166:Immunosuppressive Agents; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase